Actively Recruiting
Cord Blood Transplant in Adults With Blood Cancers
Led by Memorial Sloan Kettering Cancer Center · Updated on 2025-09-08
54
Participants Needed
1
Research Sites
261 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Cord blood transplants (CBT) are a standard treatment for adults with blood cancers. MSK has developed a standard ("optimized") practice for cord blood transplant (CBT). This optimized practice includes how patients are evaluated for transplant, the conditioning treatment (standard chemotherapy and total body irradiation therapy) given to prepare the body for transplant, the amount of stem cells transplanted, and how patients are followed during and after transplant.The purpose of this study is to collect information about participant outcomes after CBT following MSK's optimized practice. The researchers will look at outcomes of the CBT treatment such as side effects, disease relapse, GVHD, and immune system recovery after CBT treatment.
CONDITIONS
Official Title
Cord Blood Transplant in Adults With Blood Cancers
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 21 to 65 years
- Diagnosis of AML, ALL, other acute leukemias, MDS, MPD (excluding myelofibrosis), or high-risk non-Hodgkin lymphoma
- AML in first complete remission with high relapse risk or in second or greater remission
- ALL in first complete remission with high relapse risk or in second or greater remission
- Acute leukemias of ambiguous lineage with less than 5% blasts or morphologic remission with persistent aberrations
- MDS/MPD patients with intermediate-2 or high IPSS risk or life-threatening cytopenia
- Non-Hodgkin lymphoma patients in complete or partial remission meeting specified criteria
- Karnofsky performance score ≥ 80%
- Adequate organ function including creatinine clearance > 70 ml/min, bilirubin < 1.5 mg/dL, ALT < 3x upper limit of normal, pulmonary function > 60% predicted, left ventricular ejection fraction > 50%, albumin > 3.0
- Hematopoietic Cell Transplantation Comorbidity Index ≤ 5
- Cord blood units meeting specified HLA match and cell dose criteria
You will not qualify if you...
- Diagnosis of myelofibrosis or malignancy with moderate to severe bone marrow fibrosis
- Persistent central nervous system involvement or disease at screening
- Use of checkpoint inhibitors within the last 12 months
- Two or more prior stem cell transplants
- One prior autologous stem cell transplant within the past 12 months
- Prior allogeneic transplantation
- Prior radiation therapy preventing safe delivery of total body irradiation
- Active uncontrolled infection at transplant
- HIV infection or seropositivity for HTLV-1
- Inadequate performance status or organ function
- Pregnancy or breastfeeding
- Unable to provide informed consent or comply with study protocol including follow-up and tests
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
Actively Recruiting
Research Team
A
Ann Jakubowski, MD, PhD
CONTACT
A
Andromach Scaradavou, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here